Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

IntroductionRiociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension. However, there is limited data on its therapeutic use in children.Case PresentationWe report the case...

Full description

Bibliographic Details
Main Authors: L. T. Domingo, D. D. Ivy, S. H. Abman, A. M. Grenolds, J. T. MacLean, J. A. Breaux, K. J. Minford, B. S. Frank
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pediatrics
Subjects:
riociguat
pediatric pulmonary arterial hypertension
pulmonary vasodilator
targeted therapy
pulmonary vasoreactivity
TBX4 mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.1014922/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.1014922/full

Similar Items